Exercise and Pioglitazone for HIV-Metabolic Syndromes
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose is to examine the safety and efficacy of 16wks of pioglitazone (Actos; 30mg/d)
with and without aerobic and strength exercise training for reducing glucose intolerance and
central adiposity in HIV-infected people. We anticipate that pioglitazone + exercise training
will improve glucose metabolism and insulin sensitivity, and reduce central adiposity more
than pioglitazone alone. These improvements should translate into reduced cardiovascular
disease risk in HIV-infected people.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)